Christoph Salat

Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study.

Peter Wust, Ulrich Mansmann, Peter Hohenberger, 2010, The Lancet. Oncology.

Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial

Peter Wust, Ulrich Mansmann, Claus Belka, 2018, JAMA oncology.

Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers.

Carsten Denkert, Stephan Wienert, Frederick Klauschen, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

13LBA Improved overall survival by adding regional hyperthermia to neo-adjuvant chemotherapy in patients with localized high-risk soft tissue sarcoma (HR-STS): Long-term outcomes of the EORTC 62961/ESHO randomized phase III study

Ulrich Mansmann, Claus Belka, Peter Hohenberger, 2015 .

Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial

Peter A. Fasching, Carsten Denkert, Andreas Schneeweiss, 2018, BMC Medicine.